Down Regulation of Trail and Fasl on Nk Cells by Cyclosporin A in Renal Transplantation Patients

Yun Zhang,Guang Cheng,Zhu-Wei Xu,Li,Chao-Jun Song,Qi Li,Li-Hua Chen,Kun Yang,An-Gang Yang,Bo-Quan Jin
DOI: https://doi.org/10.1016/j.imlet.2013.03.002
IF: 4.23
2013-01-01
Immunology Letters
Abstract:TNF-related apoptosis-inducing ligand (TRAIL) and FasL can participate in cell mediated cytotoxicity via their death domain-mediated apoptotic signaling in the host-versus-graft disease occurred after renal transplantation. However, the effect of Cyclosporin A (CsA) commonly used as a drug to prevent and to treat renal transplant rejection, on these molecules have not been fully determined. In the present study, we found that with CsA administration, the expression of TRAIL and FasL predominantly on NK cells from renal transplantation patients was increased at day 5 after operation and went down to normal level on day 13. While, the levels of soluble TRAIL (sTRAIL) and sFasL in the serum increased within 25 days and went down to normal level three month later. In addition, we showed that a remarkable increase of TRAIL and FasL expression both on the surface of activated lymphocytes especially on NK cells and in the supernatants generated from mixed lymphocytes culture (MLC). Furthermore, the enhancement of these two molecules was greatly decreased by adding 500ng/mL CsA at the beginning of MLC. We conclude that CsA may inhibit the transplant rejection partially by down-regulating the expression of TRAIL and FasL on NK cells.
What problem does this paper attempt to address?